Reduction of early reperfusion injury with the mitochondria-targeting peptide bendavia.
Authors:
Journal: Journal of cardiovascular pharmacology and therapeutics
Publication Type: Comparative Study
Date: 2014
DOI: NIHMS605813
ID: 24288396
Abstract
We recently showed that Bendavia, a novel mitochondria-targeting peptide, reduced infarction and no-reflow across several experimental models. The purpose of this study was to determine the therapeutic timing and mechanism of action that underlie Bendavia's cytoprotective property. In rabbits exposed to in vivo ischemia/reperfusion (30/180 min), Bendavia administered 20 minutes prior to reperfusion (0.05 mg/kg/h, intravenously) reduced myocardial infarct size by ∼50% when administered for either 1 or 3 hours of reperfusion. However, when Bendavia perfusion began just 10 minutes after the onset of reperfusion, the protection against infarction and no-reflow was completely lost, indicating that the mechanism of protection is occurring early in reperfusion. Experiments in isolated mouse liver mitochondria found no discernible effect of Bendavia on blocking the permeability transition pore, and studies in isolated heart mitochondria showed no effect of Bendavia on respiratory rates. As Bendavia significantly lowered reactive oxygen species (ROS) levels in isolated heart mitochondria, the ROS-scavenging capacity of Bendavia was compared to well-known ROS scavengers using in vitro (cell-free) systems that enzymatically generate ROS. Across doses ranging from 1 nmol/L to 1 mmol/L, Bendavia showed no discernible ROS-scavenging properties, clearly differentiating itself from prototypical scavengers. In conclusion, Bendavia is a promising candidate to reduce cardiac injury when present at the onset of reperfusion but not after reperfusion has already commenced. Given that both infarction and no-reflow are related to increased cellular ROS, Bendavia's protective mechanism of action likely involves reduced ROS generation (as opposed to augmented scavenging) by endothelial and myocyte mitochondria.
Chemical List
- Free Radical Scavengers|||Mitochondrial Membrane Transport Proteins|||Mitochondrial Permeability Transition Pore|||Oligopeptides|||Reactive Oxygen Species|||arginyl-2,'6'-dimethyltyrosyl-lysyl-phenylalaninamide
Reference List
- Bolli R, Jeroudi MO, Patel BS, DuBose CM, Lai EK, Roberts R, McCay PB. Direct evidence that oxygen-derived free radicals contribute to postischemic myocardial dysfunction in the intact dog. Proceedings of the National Academy of Sciences of the United States of America. 1989;86:4695–4699.|||Garlick PB, Davies MJ, Hearse DJ, Slater TF. Direct detection of free radicals in the reperfused rat heart using electron spin resonance spectroscopy. Circulation research. 1987;61:757–760.|||Schwartz BG, Kloner RA. Coronary no reflow. Journal of molecular and cellular cardiology. 2012;52:873–882.|||Yellon DM, Dana A. The preconditioning phenomenon: A tool for the scientist or a clinical reality? Circulation research. 2000;87:543–550.|||Halestrap AP, Clarke SJ, Javadov SA. Mitochondrial permeability transition pore opening during myocardial reperfusion--a target for cardioprotection. Cardiovascular research. 2004;61:372–385.|||Baines CP. The mitochondrial permeability transition pore and ischemia-reperfusion injury. Basic research in cardiology. 2009;104:181–188.|||Brown DA, O'Rourke B. Cardiac mitochondria and arrhythmias. Cardiovascular research. 2010;88:241–249.|||Walters AM, Porter GA, Jr, Brookes PS. Mitochondria as a drug target in ischemic heart disease and cardiomyopathy. Circulation research. 2012;111:1222–1236.|||Heusch G, Boengler K, Schulz R. Inhibition of mitochondrial permeability transition pore opening: The holy grail of cardioprotection. Basic research in cardiology. 2010;105:151–154.|||Murphy E, Steenbergen C. Mechanisms underlying acute protection from cardiac ischemia-reperfusion injury. Physiological reviews. 2008;88:581–609.|||Ludman AJ, Yellon DM, Hausenloy DJ. Cardiac preconditioning for ischaemia: Lost in translation. Dis Model Mech. 2010;3:35–38.|||Downey JM, Cohen MV. Why do we still not have cardioprotective drugs? Circ J. 2009;73:1171–1177.|||Heusch G. Cardioprotection: Chances and challenges of its translation to the clinic. Lancet. 2013;381:166–175.|||Kloner RA, Schwartz Longacre L. State of the science of cardioprotection: Challenges and opportunities--proceedings of the 2010 nhlbi workshop on cardioprotection. Journal of cardiovascular pharmacology and therapeutics. 2011;16:223–232.|||Bolli R, Becker L, Gross G, Mentzer R, Jr, Balshaw D, Lathrop DA. Myocardial protection at a crossroads: The need for translation into clinical therapy. Circulation research. 2004;95:125–134.|||Schwartz Longacre L, Kloner RA, Arai AE, Baines CP, Bolli R, Braunwald E, Downey J, Gibbons RJ, Gottlieb RA, Heusch G, Jennings RB, Lefer DJ, Mentzer RM, Murphy E, Ovize M, Ping P, Przyklenk K, Sack MN, Vander Heide RS, Vinten-Johansen J, Yellon DM. New horizons in cardioprotection: Recommendations from the 2010 national heart, lung, and blood institute workshop. Circulation. 2011;124:1172–1179.|||Szeto HH. Mitochondria-targeted cytoprotective peptides for ischemia-reperfusion injury. Antioxidants & redox signaling. 2008;10:601–619.|||Kloner RA, Hale SL, Dai W, Gorman RC, Shuto T, Koomalsingh KJ, 3rd, Gorman JH, Sloan RC, Frasier CR, Watson CA, Bostian PA, Kypson AP, Brown DA. Reduction of ischemia/reperfusion injury with bendavia, a mitochondria-targeting cytoprotective peptide. J Am Heart Assoc. 2012;1:e001644.|||Chakrabarti AK, Feeney K, Abueg C, Brown DA, Czyz E, Tendera M, Janosi A, Giugliano RP, Kloner RA, Weaver WD, Bode C, Godlewski J, Merkely B, Gibson CM. Rationale and design of the embrace stemi study: A phase 2a, randomized, double-blind, placebo-controlled trial to evaluate the safety, tolerability and efficacy of intravenous bendavia on reperfusion injury in patients treated with standard therapy including primary percutaneous coronary intervention and stenting for st-segment elevation myocardial infarction. American heart journal. 2013;165:509–514. e507.|||Baines CP. The mitochondrial permeability transition pore and the cardiac necrotic program. Pediatric cardiology. 2011;32:258–262.|||Baines CP. How and when do myocytes die during ischemia and reperfusion: The late phase. Journal of cardiovascular pharmacology and therapeutics. 2011;16:239–243.|||Sloan RC, Moukdar F, Frasier CR, Patel HD, Bostian PA, Lust RM, Brown DA. Mitochondrial permeability transition in the diabetic heart: Contributions of thiol redox state and mitochondrial calcium to augmented reperfusion injury. Journal of molecular and cellular cardiology. 2012;52:1009–1018.|||Boengler K, Hilfiker-Kleiner D, Heusch G, Schulz R. Inhibition of permeability transition pore opening by mitochondrial stat3 and its role in myocardial ischemia/reperfusion. Basic research in cardiology. 2010;105:771–785.|||Skyschally A, Schulz R, Heusch G. Cyclosporine a at reperfusion reduces infarct size in pigs. Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy. 2010;24:85–87.|||Flaherty JT, Pitt B, Gruber JW, Heuser RR, Rothbaum DA, Burwell LR, George BS, Kereiakes DJ, Deitchman D, Gustafson N, et al. Recombinant human superoxide dismutase (h-sod) fails to improve recovery of ventricular function in patients undergoing coronary angioplasty for acute myocardial infarction. Circulation. 1994;89:1982–1991.|||Tsujita K, Shimomura H, Kawano H, Hokamaki J, Fukuda M, Yamashita T, Hida S, Nakamura Y, Nagayoshi Y, Sakamoto T, Yoshimura M, Arai H, Ogawa H. Effects of edaravone on reperfusion injury in patients with acute myocardial infarction. The American journal of cardiology. 2004;94:481–484.|||Leshnower BG, Kanemoto S, Matsubara M, Sakamoto H, Hinmon R, Gorman JH, 3rd, Gorman RC. Cyclosporine preserves mitochondrial morphology after myocardial ischemia/reperfusion independent of calcineurin inhibition. The Annals of thoracic surgery. 2008;86:1286–1292.|||Hale SL, Kloner RA. Cardioprotection with adenosine-regulating agent, gp531: Effects on no-reflow, infarct size, and blood flow following ischemia/ reperfusion in the rabbit. Journal of cardiovascular pharmacology and therapeutics. 2010;15:60–67.|||Frasier CR, Sloan RC, Bostian PA, Gonzon MD, Kurowicki J, Lopresto SJ, Anderson EJ, Brown DA. Short-term exercise preserves myocardial glutathione and decreases arrhythmias after thiol oxidation and ischemia in isolated rat hearts. J Appl Physiol. 2011;111:1751–1759.|||Brown DA, Aon MA, Frasier CR, Sloan RC, Maloney AH, Anderson EJ, O'Rourke B. Cardiac arrhythmias induced by glutathione oxidation can be inhibited by preventing mitochondrial depolarization. Journal of molecular and cellular cardiology. 2010;48:673–679.|||Sloan RC, Rosenbaum M, O'Rourke D, Oppelt K, Frasier CR, Waston CA, Allan AG, Brown DA. High doses of ketamine-xylazine anesthesia reduce cardiac ischemia-reperfusion injury in guinea pigs. J Am Assoc Lab Anim Sci. 2011;50:349–354.|||McGee AM, Baines CP. Phosphate is not an absolute requirement for the inhibitory effects of cyclosporin a or cyclophilin d deletion on mitochondrial permeability transition. The Biochemical journal. 2012;443:185–191.|||Anderson EJ, Lustig ME, Boyle KE, Woodlief TL, Kane DA, Lin CT, Price JW, 3rd, Kang L, Rabinovitch PS, Szeto HH, Houmard JA, Cortright RN, Wasserman DH, Neufer PD. Mitochondrial h2o2 emission and cellular redox state link excess fat intake to insulin resistance in both rodents and humans. The Journal of clinical investigation. 2009|||Gibson QH, Swoboda BE, Massey V. Kinetics and mechanism of action of glucose oxidase. The Journal of biological chemistry. 1964;239:3927–3934.|||Tao Z, Raffel RA, Souid AK, Goodisman J. Kinetic studies on enzyme-catalyzed reactions: Oxidation of glucose, decomposition of hydrogen peroxide and their combination. Biophysical journal. 2009;96:2977–2988.|||Jones DP. Radical-free biology of oxidative stress. Am J Physiol Cell Physiol. 2008;295:C849–C868.|||Kelley EE, Khoo NK, Hundley NJ, Malik UZ, Freeman BA, Tarpey MM. Hydrogen peroxide is the major oxidant product of xanthine oxidase. Free radical biology & medicine. 2010;48:493–498.|||Cope DK, Impastato WK, Cohen MV, Downey JM. Volatile anesthetics protect the ischemic rabbit myocardium from infarction. Anesthesiology. 1997;86:699–709.|||Haessler R, Kuzume K, Chien GL, Wolff RA, Davis RF, Van Winkle DM. Anaesthetics alter the magnitude of infarct limitation by ischaemic preconditioning. Cardiovascular research. 1994;28:1574–1580.|||Walsh RS, Tsuchida A, Daly JJ, Thornton JD, Cohen MV, Downey JM. Ketamine-xylazine anaesthesia permits a katp channel antagonist to attenuate preconditioning in rabbit myocardium. Cardiovascular research. 1994;28:1337–1341.|||Miller TD, Christian TF, Hopfenspirger MR, Hodge DO, Gersh BJ, Gibbons RJ. Infarct size after acute myocardial infarction measured by quantitative tomographic 99mtc sestamibi imaging predicts subsequent mortality. Circulation. 1995;92:334–341.|||Halestrap AP. What is the mitochondrial permeability transition pore? Journal of molecular and cellular cardiology. 2009;46:821–831.|||Halestrap AP, Pasdois P. The role of the mitochondrial permeability transition pore in heart disease. Biochimica et biophysica acta. 2009;1787:1402–1415.|||Bolli R. Oxygen-derived free radicals and postischemic myocardial dysfunction ("stunned myocardium") Journal of the American College of Cardiology. 1988;12:239–249.|||Bognar Z, Kalai T, Palfi A, Hanto K, Bognar B, Mark L, Szabo Z, Tapodi A, Radnai B, Sarszegi Z, Szanto A, Gallyas F, Jr, Hideg K, Sumegi B, Varbiro G. A novel sod-mimetic permeability transition inhibitor agent protects ischemic heart by inhibiting both apoptotic and necrotic cell death. Free radical biology & medicine. 2006;41:835–848.|||Chi LG, Tamura Y, Hoff PT, Macha M, Gallagher KP, Schork MA, Lucchesi BR. Effect of superoxide dismutase on myocardial infarct size in the canine heart after 6 hours of regional ischemia and reperfusion: A demonstration of myocardial salvage. Circulation research. 1989;64:665–675.|||Kilgore KS, Friedrichs GS, Johnson CR, Schasteen CS, Riley DP, Weiss RH, Ryan U, Lucchesi BR. Protective effects of the sod-mimetic sc-52608 against ischemia/reperfusion damage in the rabbit isolated heart. Journal of molecular and cellular cardiology. 1994;26:995–1006.|||Abe M, Takiguchi Y, Ichimaru S, Tsuchiya K, Wada K. Comparison of the protective effect of n-acetylcysteine by different treatments on rat myocardial ischemia-reperfusion injury. Journal of pharmacological sciences. 2008;106:571–577.|||Alberola A, Such L, Gil F, Zaragoza R, Morcillo EJ. Protective effect of n-acetylcysteine on ischaemia-induced myocardial damage in canine heart. Naunyn-Schmiedeberg's archives of pharmacology. 1991;343:505–510.|||Brunet J, Boily MJ, Cordeau S, Des Rosiers C. Effects of n-acetylcysteine in the rat heart reperfused after low-flow ischemia: Evidence for a direct scavenging of hydroxyl radicals and a nitric oxide-dependent increase in coronary flow. Free radical biology & medicine. 1995;19:627–638.|||Kingma JG, Jr, Rouleau JR. Effect of n-acetylcysteine on tissue necrosis during acute myocardial infarction in rabbits. The Canadian journal of cardiology. 1989;5:321–326.|||Sochman J, Kolc J, Vrana M, Fabian J. Cardioprotective effects of n-acetylcysteine: The reduction in the extent of infarction and occurrence of reperfusion arrhythmias in the dog. International journal of cardiology. 1990;28:191–196.|||Ross MF, Kelso GF, Blaikie FH, James AM, Cocheme HM, Filipovska A, Da Ros T, Hurd TR, Smith RA, Murphy MP. Lipophilic triphenylphosphonium cations as tools in mitochondrial bioenergetics and free radical biology. Biochemistry (Mosc) 2005;70:222–230.|||Frasier CR, Moukdar F, Patel HD, Sloan RC, Stewart LM, Alleman RJ, La Favor JD, Brown DA. Redox-dependent increases in glutathione reductase and exercise preconditioning: Role of nadph oxidase and mitochondria. Cardiovascular research. 2013;98:47–55.|||Szeto HH, Liu S, Soong Y, Wu D, Darrah SF, Cheng FY, Zhao Z, Ganger M, Tow CY, Seshan SV. Mitochondria-targeted peptide accelerates atp recovery and reduces ischemic kidney injury. Journal of the American Society of Nephrology : JASN. 2011;22:1041–1052.|||Szeto HH, Schiller PW. Novel therapies targeting inner mitochondrial membrane-from discovery to clinical development. Pharmaceutical research. 2011|||Zhao K, Zhao GM, Wu D, Soong Y, Birk AV, Schiller PW, Szeto HH. Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury. The Journal of biological chemistry. 2004;279:34682–34690.|||Birk AV, Liu S, Soong Y, Mills W, Singh P, Warren JD, Seshan SV, Pardee JD, Szeto HH. The mitochondrial-targeted compound ss-31 re-energizes ischemic mitochondria by interacting with cardiolipin. Journal of the American Society of Nephrology : JASN. 2013|||Chicco AJ, Sparagna GC. Role of cardiolipin alterations in mitochondrial dysfunction and disease. Am J Physiol Cell Physiol. 2007;292:C33–C44.|||Brown DA, Sabbah HN, Shaikh SR. Mitochondrial inner membrane lipids and proteins as targets for decreasing cardiac ischemia/reperfusion injury. Pharmacology & therapeutics. 2013|||Hausenloy DJ, Tsang A, Mocanu MM, Yellon DM. Ischemic preconditioning protects by activating prosurvival kinases at reperfusion. American journal of physiology. 2005;288:H971–H976.|||Kin H, Zhao ZQ, Sun HY, Wang NP, Corvera JS, Halkos ME, Kerendi F, Guyton RA, Vinten-Johansen J. Postconditioning attenuates myocardial ischemia-reperfusion injury by inhibiting events in the early minutes of reperfusion. Cardiovascular research. 2004;62:74–85.|||Piot C, Croisille P, Staat P, Thibault H, Rioufol G, Mewton N, Elbelghiti R, Cung TT, Bonnefoy E, Angoulvant D, Macia C, Raczka F, Sportouch C, Gahide G, Finet G, Andre-Fouet X, Revel D, Kirkorian G, Monassier JP, Derumeaux G, Ovize M. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. The New England journal of medicine. 2008;359:473–481.|||Matsumoto-Ida M, Akao M, Takeda T, Kato M, Kita T. Real-time 2-photon imaging of mitochondrial function in perfused rat hearts subjected to ischemia/reperfusion. Circulation. 2006;114:1497–1503.|||Slodzinski MK, Aon MA, O'Rourke B. Glutathione oxidation as a trigger of mitochondrial depolarization and oscillation in intact hearts. Journal of molecular and cellular cardiology. 2008;45:650–660.|||Yang XM, Liu Y, Cui L, Yang X, Liu Y, Tandon N, Kambayashi J, Downey JM, Cohen MV. Two classes of anti-platelet drugs reduce anatomical infarct size in monkey hearts. Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy. 2013;27:109–115.|||Dai DF, Chen T, Szeto H, Nieves-Cintron M, Kutyavin V, Santana LF, Rabinovitch PS. Mitochondrial targeted antioxidant peptide ameliorates hypertensive cardiomyopathy. Journal of the American College of Cardiology. 2011;58:73–82.|||Sabbah HN, Gupta RC, Szekely K, Wang M, Zhang K, Rstogi S. Bendavia (mtp-131), a novel mitochondria-targeting peptide, improves activity and expression of cytochrome c oxidase and attenuates mediators of cardiomyocyte apoptosis in left ventricular myocardium of dogs with advanced heart failure. Journal of the American College of Cardiology. 2013;61